Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.

Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehrl E, Berney M.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0014-2016.

PMID:
28597820
2.

Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.

Kwon YS.

Chonnam Med J. 2017 May;53(2):103-109. doi: 10.4068/cmj.2017.53.2.103. Epub 2017 May 25. Review.

3.

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities.

Xia X, Pethe K, Kim R, Ballell L, Barros D, Cechetto J, Jeon H, Kim K, Garcia-Bennett AE.

Nanomaterials (Basel). 2014 Sep 11;4(3):813-826. doi: 10.3390/nano4030813.

4.

Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Gold B, Nathan C.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0031-2016. Review.

5.

Metabolic Perspectives on Persistence.

Hartman TE, Wang Z, Jansen RS, Gardete S, Rhee KY.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TBTB2-0026-2016. Review.

6.

Discovery and characterization of an F420-dependent glucose-6-phosphate dehydrogenase (Rh-FGD1) from Rhodococcus jostii RHA1.

Nguyen QT, Trinco G, Binda C, Mattevi A, Fraaije MW.

Appl Microbiol Biotechnol. 2017 Apr;101(7):2831-2842. doi: 10.1007/s00253-016-8038-y. Epub 2016 Dec 13.

7.

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania.

Wyllie S, Roberts AJ, Norval S, Patterson S, Foth BJ, Berriman M, Read KD, Fairlamb AH.

PLoS Pathog. 2016 Nov 3;12(11):e1005971. doi: 10.1371/journal.ppat.1005971. eCollection 2016 Nov.

8.

The redox cofactor F420 protects mycobacteria from diverse antimicrobial compounds and mediates a reductive detoxification system.

Jirapanjawat T, Ney B, Taylor MC, Warden AC, Afroze S, Russell RJ, Lee BM, Jackson CJ, Oakeshott JG, Pandey G, Greening C.

Appl Environ Microbiol. 2016 Sep 16. pii: AEM.02500-16. [Epub ahead of print]

9.

Recent developments and future prospects in the treatment of visceral leishmaniasis.

Sundar S, Singh A.

Ther Adv Infect Dis. 2016 Jun;3(3-4):98-109. doi: 10.1177/2049936116646063. Epub 2016 Apr 22. Review.

10.

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.

Patterson S, Wyllie S, Norval S, Stojanovski L, Simeons FR, Auer JL, Osuna-Cabello M, Read KD, Fairlamb AH.

Elife. 2016 May 24;5. pii: e09744. doi: 10.7554/eLife.09744.

11.

Role of Alanine Dehydrogenase of Mycobacterium tuberculosis during Recovery from Hypoxic Nonreplicating Persistence.

Giffin MM, Shi L, Gennaro ML, Sohaskey CD.

PLoS One. 2016 May 20;11(5):e0155522. doi: 10.1371/journal.pone.0155522. eCollection 2016.

12.

F420H2 Is Required for Phthiocerol Dimycocerosate Synthesis in Mycobacteria.

Purwantini E, Daniels L, Mukhopadhyay B.

J Bacteriol. 2016 Jul 13;198(15):2020-8. doi: 10.1128/JB.01035-15. Print 2016 Aug 1.

13.

Combating Tuberculosis Infection: A Forbidding Challenge.

Rawal T, Butani S.

Indian J Pharm Sci. 2016 Jan-Feb;78(1):8-16. Review.

14.

Does Concurrent Use of Some Botanicals Interfere with Treatment of Tuberculosis?

Folk WR, Smith A, Song H, Chuang D, Cheng J, Gu Z, Sun G.

Neuromolecular Med. 2016 Sep;18(3):483-6. doi: 10.1007/s12017-016-8402-1. Epub 2016 May 7. Review.

PMID:
27155670
15.

Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.

Greening C, Ahmed FH, Mohamed AE, Lee BM, Pandey G, Warden AC, Scott C, Oakeshott JG, Taylor MC, Jackson CJ.

Microbiol Mol Biol Rev. 2016 Apr 27;80(2):451-93. doi: 10.1128/MMBR.00070-15. Print 2016 Jun. Review.

16.

Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.

Majewski MW, Tiwari R, Miller PA, Cho S, Franzblau SG, Miller MJ.

Bioorg Med Chem Lett. 2016 Apr 15;26(8):2068-71. doi: 10.1016/j.bmcl.2016.02.076. Epub 2016 Feb 27.

17.
18.

Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Rakesh, Bruhn DF, Scherman MS, Singh AP, Yang L, Liu J, Lenaerts AJ, Lee RE.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):388-91. doi: 10.1016/j.bmcl.2015.12.002. Epub 2015 Dec 7.

19.

First-in-Class Inhibitors of Sulfur Metabolism with Bactericidal Activity against Non-Replicating M. tuberculosis.

Palde PB, Bhaskar A, Pedr├│ Rosa LE, Madoux F, Chase P, Gupta V, Spicer T, Scampavia L, Singh A, Carroll KS.

ACS Chem Biol. 2016 Jan 15;11(1):172-84. doi: 10.1021/acschembio.5b00517. Epub 2015 Nov 11.

20.

glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival.

Gutka HJ, Wang Y, Franzblau SG, Movahedzadeh F.

PLoS One. 2015 Sep 23;10(9):e0138436. doi: 10.1371/journal.pone.0138436. eCollection 2015.

Supplemental Content

Support Center